ap20187 and Teratoma

ap20187 has been researched along with Teratoma* in 2 studies

Other Studies

2 other study(ies) available for ap20187 and Teratoma

Article	Year
Improving the safety of human pluripotent stem cell therapies using genome-edited orthogonal safeguards. Nature communications, 2020, 06-01, Volume: 11, Issue:1 Despite their rapidly-expanding therapeutic potential, human pluripotent stem cell (hPSC)-derived cell therapies continue to have serious safety risks. Transplantation of hPSC-derived cell populations into preclinical models has generated teratomas (tumors arising from undifferentiated hPSCs), unwanted tissues, and other types of adverse events. Mitigating these risks is important to increase the safety of such therapies. Here we use genome editing to engineer a general platform to improve the safety of future hPSC-derived cell transplantation therapies. Specifically, we develop hPSC lines bearing two drug-inducible safeguards, which have distinct functionalities and address separate safety concerns. In vitro administration of one small molecule depletes undifferentiated hPSCs >10 Topics: Animals; Cell Culture Techniques; Cell Differentiation; Cell Survival; Gene Editing; Green Fluorescent Proteins; Humans; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Nanog Homeobox Protein; Pluripotent Stem Cells; Small Molecule Libraries; Stem Cell Transplantation; Tacrolimus; Teratoma	2020
Using the Inducible Caspase-9 Suicide-Safeguard System with iPSC and Bioluminescent Tracking. Methods in molecular biology (Clifton, N.J.), 2019, Volume: 2048 For scientists working within the field of induced pluripotent stem cells (iPSCs), this protocol will provide a thorough walk-through on how to conduct in vitro and in vivo experiments that validate the function of a particular safeguard system technology. In short, we provide instructions on how to generate inducible Caspase-9 (iC9) safeguard system with human iPSCs that act as normal or abnormal models of the cells for therapeutics to be tried after differentiation. These iC9-iPSCs should be modified prior to beginning this protocol by constitutively expressing luciferase, an enzyme capable of generating bioluminescent signals through the oxidation of the substrate luciferin. Monitoring the bioluminescent signal over time provides the information on whether a safeguard system is working or not. Topics: Animals; Benzothiazoles; Caspase 9; Cell Culture Techniques; Cell Differentiation; Cell Line; Culture Media; Disease Models, Animal; Gene Expression; Genes, Reporter; Genes, Transgenic, Suicide; Humans; Immunotherapy; Induced Pluripotent Stem Cells; Injections, Intraperitoneal; Intravital Microscopy; Luciferases, Firefly; Luminescent Measurements; Mice, Inbred NOD; Mice, SCID; Tacrolimus; Teratoma; Tumor Burden	2019

Article

Year

Improving the safety of human pluripotent stem cell therapies using genome-edited orthogonal safeguards.

Nature communications, 2020, 06-01, Volume: 11, Issue:1

Despite their rapidly-expanding therapeutic potential, human pluripotent stem cell (hPSC)-derived cell therapies continue to have serious safety risks. Transplantation of hPSC-derived cell populations into preclinical models has generated teratomas (tumors arising from undifferentiated hPSCs), unwanted tissues, and other types of adverse events. Mitigating these risks is important to increase the safety of such therapies. Here we use genome editing to engineer a general platform to improve the safety of future hPSC-derived cell transplantation therapies. Specifically, we develop hPSC lines bearing two drug-inducible safeguards, which have distinct functionalities and address separate safety concerns. In vitro administration of one small molecule depletes undifferentiated hPSCs >10

Topics: Animals; Cell Culture Techniques; Cell Differentiation; Cell Survival; Gene Editing; Green Fluorescent Proteins; Humans; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Nanog Homeobox Protein; Pluripotent Stem Cells; Small Molecule Libraries; Stem Cell Transplantation; Tacrolimus; Teratoma

2020

Using the Inducible Caspase-9 Suicide-Safeguard System with iPSC and Bioluminescent Tracking.

Methods in molecular biology (Clifton, N.J.), 2019, Volume: 2048

For scientists working within the field of induced pluripotent stem cells (iPSCs), this protocol will provide a thorough walk-through on how to conduct in vitro and in vivo experiments that validate the function of a particular safeguard system technology. In short, we provide instructions on how to generate inducible Caspase-9 (iC9) safeguard system with human iPSCs that act as normal or abnormal models of the cells for therapeutics to be tried after differentiation. These iC9-iPSCs should be modified prior to beginning this protocol by constitutively expressing luciferase, an enzyme capable of generating bioluminescent signals through the oxidation of the substrate luciferin. Monitoring the bioluminescent signal over time provides the information on whether a safeguard system is working or not.

Topics: Animals; Benzothiazoles; Caspase 9; Cell Culture Techniques; Cell Differentiation; Cell Line; Culture Media; Disease Models, Animal; Gene Expression; Genes, Reporter; Genes, Transgenic, Suicide; Humans; Immunotherapy; Induced Pluripotent Stem Cells; Injections, Intraperitoneal; Intravital Microscopy; Luciferases, Firefly; Luminescent Measurements; Mice, Inbred NOD; Mice, SCID; Tacrolimus; Teratoma; Tumor Burden

2019